Rethinking Recurrence: PIK3CA Mutations in HR+, HER2- Breast Cancer
Early-stage breast cancer patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors face a big challenge: disease recurrence. This kind of cancer is diverse and tricky to manage because a quarter of these patients will see their disease come b